Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7873424 | 0.87 | ADRA1A (0.54) | ADRA1AADRA1BKDM4EGLAKMT2A | |
| SCHEMBL10884917 | 0.87 | ADRA1A (0.54) | ADRA1AADRA1BKDM4EGLAKMT2A | |
| SCHEMBL6197980 | 0.84 | ADRA1A (0.57) | ADRA1AADRA1BKDM4EGLAKMT2A | |
| SCHEMBL4664637 | 0.84 | ADRA1A (0.55) | ADRA1AADRA1BKDM4EGLAKMT2A | |
| SCHEMBL2707530 | 0.84 | KDM4E (0.66) | ADRA1AADRA1BKDM4EGLAKMT2A | |
| SCHEMBL31518562 | 0.83 | KDM4E (0.57) | ADRA1AADRA1BKDM4EGLAKMT2A | |
| SCHEMBL8837258 | 0.83 | ALDH1A1 (0.55) | ADRA1AADRA1BKDM4EGLAKMT2A | |
| SCHEMBL7439245 | 0.82 | ADRA1A (0.55) | ADRA1AADRA1BKDM4EGLAKMT2A | |
| SCHEMBL1643649 | 0.82 | KDM4E (0.72) | ADRA1AADRA1BKDM4EGLAKMT2A | |
| SCHEMBL4629588 | 0.81 | EGFR (0.49) | ADRA1AADRA1BKDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241922-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | claimed |
| US-20250241921-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | claimed |
| US-20240197741-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA(SHANGHAI)CO., LTD. (CN) | 2024-06-20 | — | — | US | claimed |
| CN-117355527-B | Anti-inflammatory coupling compound medicine and preparation method and application thereof | 上海椿安生物医药科技有限公司 | 2024-06-07 | — | — | CN | claimed |
| EP-4357346-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Coval Biopharma (Shanghai) Co., Ltd. (CN) | 2024-04-24 | — | — | EP | claimed |
| CN-117355527-A | External anti-inflammatory coupling compound medicine and preparation method and application thereof | 上海椿安生物医药科技有限公司 | 2024-01-05 | — | — | CN | claimed |
| WO-2023001045-A9 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海椿安生物医药科技有限公司 | 2023-10-26 | — | — | WO | claimed |
| CN-112500361-B | Preparation method of (S) -4-phenyl-2-oxazolidinone | 甘肃瀚聚药业有限公司 | 2023-05-12 | — | — | CN | claimed |
| WO-2023001045-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海椿安生物医药科技有限公司 | 2023-01-26 | — | — | WO | claimed |
| CN-110981887-B | Dihydroartemisinin compounds, and preparation method and medical application thereof | 延边大学 | 2022-05-17 | — | — | CN | claimed |
| CN-112500361-A | Preparation method of (S) -4-phenyl-2-oxazolidinone | 甘肃瀚聚药业有限公司 | 2021-03-16 | — | — | CN | claimed |
| US-9828334-B2 | Process for preparing levomilnacipran | OLON S.P.A. (IT) | 2017-11-28 | — | — | US | claimed |
| US-20250304603-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | ZHOU YUHANG (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250241922-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-20250241921-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-3957768-A | BACTERICIDES | SMITHKLINE CORPORATION (US) | 1976-05-18 | — | — | US | disclosed |
| US-3953436-A | 3,4-Dicarboxycephalosporins and derivatives | ELI LILLY AND COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
| US-3946005-A | BACTERICIDES | SMITHKLINE CORPORATION (US) | 1976-03-23 | — | — | US | disclosed |
| US-3943129-A | BACTERICIDE | SMITHKLINE CORPORATION (US) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241921-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JAK1, TNF, CYP4A11 | ADRA1A 740/4885ADRA1B 386/4885KDM4E 1850/4885 |
| US-20250304603-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | ADRA1A 1441/4885ADRA1B 389/4885KDM4E 2081/4885 |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | PF4, F12, F2 | ADRA1A 3830/4885ADRA1B 3690/4885KDM4E 1473/4885 |
| US-20250241922-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JAK1, TNF, CYP4A11 | ADRA1A 740/4885ADRA1B 386/4885KDM4E 1850/4885 |
| US-20240197741-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | TNF, CYP4A11, JAK1 | ADRA1A 661/4885ADRA1B 394/4885KDM4E 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.